Apixaban had 9,055 Medicare beneficiaries in 2013. By 2023, it had 4,191,162. That's not a drug gaining market share. That's a near-complete replacement of an entire therapeutic category, and it happened while the cost per patient rose 52%, from $2,723.05 to $4,149.72 per year.

The headline math is stark: $17,392,162,956 in total Medicare spending on apixaban alone in 2023, up from $24,657,203 a decade earlier. That's a 70,500% increase in total program cost driven by a combination of volume and price that the system absorbed without much public accounting.

From Niche Drug to Medicare's Dominant Anticoagulant

Warfarin, the old standard, costs roughly $10 a month. The newer direct oral anticoagulants (DOACs) like apixaban run closer to $400. The clinical case for the switch is real: DOACs require no routine INR monitoring, have fewer food and drug interactions, and in many patients carry a better safety profile. But the financial consequences for Medicare are now enormous.

Dabigatran, the first DOAC to gain traction, had 99,104 beneficiaries in 2013 compared to apixaban's 9,055. By 2023, that relationship had inverted completely. Dabigatran's cost per beneficiary peaked at $6,424.37 in 2017 before falling to $3,842.94 in 2021, likely as generic competition entered. Apixaban, by contrast, kept climbing. For Medicare beneficiaries with atrial fibrillation or venous thromboembolism, the shift to apixaban represents a permanent, large, and ongoing cost increase per patient.

The per-patient cost difference matters because it compounds. Four million patients paying $1,400 more per year than they would on warfarin is $5.6 billion in annual incremental spending, before accounting for any monitoring costs warfarin would have required.

Who's Writing These Prescriptions Now

The specialty breakdown tells a story about how prescribing authority has changed as much as how drug preferences have.

Cardiology, the obvious home for anticoagulation management, grew DOAC claims 333.1%, from 1,296,830 in 2013 to 5,616,666 in 2023. That's substantial growth, but it's the slowest rate among the major specialties. Nurse Practitioners grew DOAC claims by 4,156.6%, from 89,787 to 3,821,881 claims. Family Practice added 4,903,411 claims in absolute terms, reaching 5,263,888 by 2023.

The Interventional Cardiology number is genuinely difficult to interpret at face value. Starting from 40 claims in 2013 and reaching 1,142,468 in 2023 represents a 2,856,070% increase. Whether that reflects a reclassification of billing codes, a structural change in how post-procedural anticoagulation is managed, or something else entirely is a question the data raises but doesn't answer.

The Cost Structure Nobody Planned For

The broader picture is a Medicare drug benefit that absorbed a category-level pricing shift without a corresponding policy response. When millions of patients move from a $10-a-month drug to a $400-a-month drug, and the prescribing base expands to include primary care, nurse practitioners, and physician assistants at scale, the total cost trajectory becomes very hard to reverse.

Apixaban's per-beneficiary cost of $4,149.72 in 2023 is 52% higher than it was in 2013, even as the drug has been on the market long enough that generic pressure might have been expected to moderate prices. It hasn't, at least not yet. The Inflation Reduction Act's drug negotiation provisions include apixaban on the list of drugs subject to Medicare price negotiation, which means the 2023 figures may represent a high-water mark. But with 4.2 million beneficiaries now dependent on the drug, even a negotiated price reduction leaves a program cost structure that looks nothing like what existed when the first DOAC prescriptions were written a decade ago.

The question embedded in that Interventional Cardiology number, 40 claims to 1.1 million in ten years, is whether the clinical expansion of DOAC prescribing into procedural specialties represents appropriate guideline-driven care or something more complicated. At $4,149.72 per patient per year, the answer has a nine-figure price tag attached to it.